GSEP
PYXS icon

Golden State Equity Partners’s Pyxis Oncology PYXS Stock Holding History

Golden State Equity Partners’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14 Buy
+10
New +$15 ﹤0.01% 2012

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Golden State Equity Partners's PYXS Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in Pyxis Oncology (PYXS) in Q1 2026: 10 shares worth $14. The stake represents ﹤0.01% of the portfolio and ranks #2012 among its holdings.

78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Golden State Equity Partners held 10 shares of Pyxis Oncology worth $14 as of Q1 2026.
  • Pyxis Oncology was a new Golden State Equity Partners position in Q1 2026.
  • Pyxis Oncology made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #2012 holding.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.